A gut-microbe supplement slowed weight regain in a small maintenance trial

The idea that a single gut bacterium could blunt weight regain has been circulating for a decade, built largely on mouse studies and one small human pilot. A randomised trial published in Nature Medicine now offers the strongest human test yet — and a reminder to read the funding line before the headline [s1].

What the trial did

Ninety adults with overweight or obesity first went through an eight-week low-energy diet designed to take off at least 8% of their body weight [s1]. They then entered a 24-week maintenance phase on a healthy, eat-to-appetite diet, randomised to take either a daily dose of pasteurised Akkermansia muciniphila MucT or a placebo [s1]. The primary outcome was the change in body weight during that maintenance period — that is, how much of the lost weight came back [s1].

Akkermansia muciniphila is a mucus-dwelling gut microbe whose abundance is inversely correlated with obesity and metabolic disease in observational data [s2]. Preclinical work suggested it could prevent diet-induced obesity, and a 2019 proof-of-concept study in overweight and obese volunteers found the pasteurised form was safe and hinted at metabolic benefit, but it was explicitly exploratory [s2].

The numbers

Over the maintenance period, the supplement group regained less weight than placebo: 1.2 ± 0.7 kg versus 3.2 ± 0.4 kg (P = 0.012) [s1]. Measured from the pre-diet baseline to the end of maintenance, the supplement group's net weight loss was greater than placebo's by 3.1 ± 0.7 kg (P = 0.009) [s1]. The authors also reported that participants' initial Akkermansia abundance was associated with their cardiometabolic response to the supplement, hinting that the people who benefit most may be identifiable in advance [s1]. No serious adverse events related to the treatment were observed [s1].

The effect is real in the trial but modest in size — a difference of about two kilograms of regain across nearly six months, in 90 people [s1]. It is worth being precise about what "maintenance" meant here: after the eight-week low-energy diet, everyone had already lost at least 8% of their starting weight, and the trial then measured how well each group held onto that loss while eating freely [s1]. Both groups regained some weight; the supplement group simply regained less [s1]. That is a narrower and more realistic claim than "a supplement that makes you lose weight," and it matches the way the drug is positioned — as an aid to keeping weight off after it has come down.

Read the funding line

This is where caution belongs. The trial was sponsored by The Akkermansia Company, the Belgian firm that commercialises the exact supplement being tested [s1]. Company sponsorship does not make a result wrong, and publication in a high-bar journal with a placebo control and a prespecified primary outcome is a genuine strength. But it does mean the trial was designed and paid for by the party with a commercial stake in a positive answer, and that context should travel with the finding.

The limits the authors themselves flag

The paper is unusually candid about what it cannot show. It was a relatively short-term intervention, so whether the effect persists beyond six months is unknown [s1]. And it lacked an arm receiving a modified strain of MucT stripped of its active components — the kind of control that would help pin the effect to the specific mechanism rather than to the intervention generally [s1]. The trial was also small, which widens the uncertainty around a two-kilogram difference and limits any read on subgroups.

There is also the gap between "less regain" and clinical benefit. The trial measured body weight, not cardiovascular events, diabetes incidence or any hard outcome, and it ran in people who had just completed a supervised weight-loss diet — not a general population reaching for a supplement off a shelf [s1]. A microbe that helps hold onto diet-induced weight loss under trial conditions is not the same as a weight-loss product.

What to watch

The result moves Akkermansia from "interesting in mice and one pilot" to "showed a modest, prespecified effect in a controlled human trial" — a real step, but a first one [s1]. The tests that would matter next are independent replication not funded by the manufacturer, longer follow-up to see whether the weight difference holds or fades, and the mechanistic control arm the authors say is missing. Until then, the honest summary is a small effect, in a small trial, paid for by the company that sells the product.

This article is informational and does not constitute medical advice.

Sources

• [s1] Pasteurized Akkermansia muciniphila MucT for weight loss maintenance in people with overweight and obesity: a controlled randomized trial. Nature Medicine, 13 May 2026. https://doi.org/10.1038/s41591-026-04394-7
• [s2] Supplementation with Akkermansia muciniphila in overweight and obese human volunteers: a proof-of-concept exploratory study. Nature Medicine, 1 July 2019. https://doi.org/10.1038/s41591-019-0495-2